menu
    • menu
    [{"orgOrder":0,"company":"Arugula Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"SIG001","moa":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Arugula Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Arugula Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arugula Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Arugula Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"SIG002","moa":"","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Arugula Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Arugula Sciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Arugula Sciences \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Arugula Sciences

    Menu

    Arugula Sciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Arugula Sciences

                            U.S.A arrow
                            Duphat
                            Not Confirmed

                            Arugula Sciences

                            U.S.A arrow
                            Duphat
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SIG002

                            Therapeutic Area : Musculoskeletal

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Arugula Sciences Announces FDA Approval to Proceed with Phase 1 Study of SIG002, a Perinatal-derived Secretome...

                            Details : SIG002 consists purified secretome free of tissue fragments and cells. SIG002 has demonstrated immunoregulatory properties relevant to address the degenerative inflammatory processes involved in osteoarthritis disease etiology.

                            Brand Name : SIG002

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            January 31, 2023

                            Lead Product(s) : SIG002

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Arugula Sciences

                            U.S.A arrow
                            Duphat
                            Not Confirmed

                            Arugula Sciences

                            U.S.A arrow
                            Duphat
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SIG001

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Arugula Sciences Announces Company Launch with FDA Phase 1 Approval for Osteoarthritis Therapy

                            Details : SIG001 (Signature Cord Prime) is an intra-articular injection human Umbilical Cord Allograft. Product is under FDA Phase 1 clinical trial to test its clinical effect on patients with symptomatic knee osteoarthritis.

                            Brand Name : SIG001

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            January 04, 2023

                            Lead Product(s) : SIG001

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth